CN105601670A - Chromium (III) complex as well as preparation method and application thereof - Google Patents
Chromium (III) complex as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN105601670A CN105601670A CN201610146067.5A CN201610146067A CN105601670A CN 105601670 A CN105601670 A CN 105601670A CN 201610146067 A CN201610146067 A CN 201610146067A CN 105601670 A CN105601670 A CN 105601670A
- Authority
- CN
- China
- Prior art keywords
- chromium
- iii
- complex
- preparation
- equal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000010668 complexation reaction Methods 0.000 title 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 10
- WHSXTWFYRGOBGO-UHFFFAOYSA-N o-cresotic acid Natural products CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 claims abstract description 10
- UYDGECQHZQNTQS-UHFFFAOYSA-N 2-amino-4,6-dimethylpyridine-3-carboxamide Chemical compound CC1=CC(C)=C(C(N)=O)C(N)=N1 UYDGECQHZQNTQS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000013078 crystal Substances 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 8
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229960001124 trientine Drugs 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 239000011651 chromium Substances 0.000 claims description 34
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 25
- 229910052804 chromium Inorganic materials 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 3
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 claims description 3
- 244000061458 Solanum melongena Species 0.000 claims description 2
- PHFQLYPOURZARY-UHFFFAOYSA-N chromium trinitrate Chemical compound [Cr+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PHFQLYPOURZARY-UHFFFAOYSA-N 0.000 claims description 2
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940046374 chromium picolinate Drugs 0.000 description 3
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 3
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011636 chromium(III) chloride Substances 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- -1 nicotinate chromium Chemical compound 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000370738 Chlorion Species 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910001430 chromium ion Inorganic materials 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000479 mixture part Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
- C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a chromium (III) complex as well as a preparation method and application thereof. According to the chromium (III) complex, the molecular formula is CrC14H26N4O4Cl, the molecular weight is 402, the crystal structure belongs to a triclinic crystal system, the spatial point group is P-1, a is equal to 7.8880(6), b is equal to 9.8380(7), c is equal to 14.4490(12) angstroms, alpha is equal to 70.4550(10), beta is equal to 85.729(2), gamma is equal to 82.0880(10) degrees, V is equal to 1046.12(14) cubic angstroms, and Z is equal to 2. The preparation method comprises the steps of dissolving chromium (III) and 3-methyl-salicylic acid by virtue of an organic solvent, feeding a small amount of zinc granules, carrying out heating reflux, then dropwise adding triethylene tetramine, continuing to carry out reflux for a period of time, stopping reaction, cooling, filtering, standing obtained filtrate, and naturally volatilizing at the normal temperature, so as to obtain purple red crystals. The chromium (III) complex can be applied to the preparation of sugar-reducing medicines.
Description
Technical field:
The present invention relates to metal complex, being specially a kind of is the chromium (III) of mixture part based on 3-methyl-salicylic acid and triethylene tetramineComplex and its preparation method and application.
Background technology:
Chromium is the trace element of needed by human. Trivalent chromium is the element useful to human body, and still, the physiological function of chromium is and otherThe material of controlling metabolism coordinates and works together, as the genetic stew of hormone, insulin, various enzyme, cell (DNA and RNA)Deng. Research shows, diabetic's chromium obviously lowers, and chromium level and blood sugar are negative correlation. Chromium (III) content in human body along withThe increase at age reduces gradually, lacks chromium (III) and can make the Reduced susceptibility of tissue to insulin, easily suffers from diabetes and AtherosclerosisChange. Can strengthen the effect of insulin to the supplementary appropriate chromium (III) of diabetes patient, the glucose tolerance that slowly-releasing human body is impaired, reduces bloodSugar level and cholesterol in serum content. At present, the chromium supplementing agent of selling on market has nicotinate chromium, amino acid chromium and chromium picolinateDeng commodity, wherein chromium picolinate is current the most salable nutrition chromium supplementing agent. But related documents report in the recent period: chromium picolinateMay cause chromosome damage, DNA mutation and cancer, and intestinal absorption rate low (< 3%), its use causes people graduallyQuery. Therefore, the substitute of finding more effective chromium picolinate becomes study hotspot, synthesizing efficient, easy absorption, low toxicityNovel Organic Chromium (III) complex significant.
Summary of the invention:
The object of the present invention is to provide a kind of preparation method and this complex of chromium (III) complex with hypoglycemic weight losing functionIn the application of preparing in hypoglycemic slimming medicine.
A kind of chromium provided by the invention (III) complex, its molecular structural formula is:
The preparation method of a kind of chromium provided by the invention (III) complex, reaction equation:
Preparation process comprises:
1) by chromic salts and 3-methyl-salicylic acid organic solvent dissolution, drop into zinc granule, add hot reflux 1～3 hour, then splash intoTriethylene tetramine, continues to reflux at least 1～2 hours, stops reaction, cooling, filters;
2) filtrate obtaining is left standstill, under normal temperature, volatilization naturally, obtained aubergine crystal after three days.
Step 1) described chromic salts is chromium chloride, chromic nitrate or chromium sulfate.
Step 1) the amount of substance ratio of described chromic salts, 3-methyl-salicylic acid and zinc granule is 1: 1: 0.5～1.65.
Step 1) described chromic salts and the amount of substance ratio of triethylene tetramine be 1: 50～100.
Step 1) described zinc granule is 20～50 object arsenic-free zinc granules.
Step 1) described organic solvent is methyl alcohol or ethanol.
Chromium (III) complex good water solubility prepared by the present invention, stability is moderate, and it is peculiar to take full advantage of 3-methyl-salicylic acid selfBiologically active and the blood sugar reducing function of chromic salts, play the collaborative biological effect of biological hypoglycemic. Animal hypoglycemic fat-reducing activity experimentShow, compared with nutritional agents chromium picolinate, this complex has remarkable effect at control animal blood glucose lipid aspects, and hasWish to apply preparing in hypoglycemic slimming medicine.
Brief description of the drawings
The crystal x-ray diffraction pattern of Fig. 1 chromium of the present invention (III) complex
The uv-visible absorption spectra of Fig. 2 chromium of the present invention (III) complex
Fluorescence spectrum (the λ of Fig. 3 chromium of the present invention (III) complexex＝300nm)
Detailed description of the invention:
Embodiment 1: preparation and the structural characterization of chromium (III) complex
Take 2.67g (10.0mmol) CrCl3·6H2O and 1.52g (10.0mmol) 3-methyl-salicylic acid (3-CH3-SA), be placed inIn 100mL round-bottomed flask, add 50mL methyl alcohol to dissolve, then add 0.30g without arsenic Zn grain, add hot reflux 1 hour,Then slowly add 0.5mL triethylene tetramine (Trientine), treat that the color of solution slowly becomes redness from green, continue reaction 1Individual hour, cooling, suction filtration, filtrate normal temperature volatilizees naturally, after three days, obtains red crystals, and productive rate is 60%.
Determination of elemental analysis result, by molecular formula CrC14H26N4O4Cl theoretical value (%): C, 41.79; H, 6.47; N,13.93; Experiment value (%): C, 41.55; H, 6.69; N, 13.88.
Crystal structure determination result (seeing accompanying drawing 1): complex molecule formula is CrC14H26N4O4Cl, molecular weight is 402, three oblique crystalline substancesSystem, space group is P-1, a=7.8880 (6), b=9.8380 (7),α＝70.4550(10)，β＝85.729(2)，γ＝82.0880(10)°，Z=2. The interior boundary of complex is by chromium ion, 1 3-firstBase-salicylate and 1 triethylene tetramine form hexa-coordinate octahedral structure; The external world is made up of 1 chlorion and 1 hydrone.Complex part bond distanceAnd bond angle (°) in table 1.
Table 1 complex part bond distanceAnd bond angle (°)
Uv-visible absorption spectra (seeing accompanying drawing 2): part 239 and 308nm place have characteristic absorption peak (curve a), with Cr3+Joinπ-the π of its phenyl ring behind position*Absworption peak respectively red shift to 285 and 338nm (curve b), illustrate electron cloud in pi-conjugated system toCr3+Empty d track shift; Complex is Cr in the absworption peak of 549nm appearance is attributed to complex3+D-d transition peak.
Near fluorescence spectrum (seeing accompanying drawing 3): part has strong fluorescence (curve a), as itself and Cr 420nm3+Form complex(curve b) by serious cancellation near fluorescence rear 420nm.
Embodiment 2: the preparation of chromium (III) complex
Take 2.67g (10.0mmol) CrCl3·6H2O and 1.52g (10.0mmol) 3-methyl-salicylic acid is placed in 100mL round bottomIn flask, add 50mL ethanol, then add 1.0g arsenic-free zinc granule, agitating heating refluxes 2 hours, slowly adds 1mLTriethylene tetramine, the color of solution slowly becomes redness from green, continues agitating heating back flow reaction about 2 hours, cooling,Normal temperature volatilizees naturally, after 3 days, obtains red crystals, and productive rate is 75%.
Embodiment 3: the active application of hypoglycemic fat-reducing of chromium (III) complex
Test to verify that by feeding small white mouse the hypoglycemic fat-reducing of chromium (III) complex is active. Test small white mouse used by Shanxi Province's traditional Chinese medical scienceMedicine research institute Experimental Animal Center provides. We choose 48 of Kunming mouses, wherein male half and half, weight range 12～15g;15～25 DEG C of room temperature conditions, relative humidity 30%～40%, natural lighting, allows ad lib and drinking-water. Normal diet is by northJing Suolaibao Science and Technology Ltd. provides. High lipid food formula: general food 66.5%, sucrose 20%, lard 10%, cholesterol 2.5%With sodium taurocholate 1%. By body weight, mouse is divided into 4 groups at random, wherein 12 of normal group, 12 of model group, positive controls12,12 of administration groups. From experiment at the beginning, give normal group mouse normal diet, all the other respectively organize equal feeding high lipid food,Last 50 days, modeling success. Then start administration, wherein normal group and model group adopt physiological saline in contrast, positive rightAdopt Cr (Pic) according to group3The aqueous solution, Cr (Pic)3Dosage is 50mg/kg, and administration group adopts the aqueous solution of this chromic compound, dosageFor 60mg/kg, every morning 9:00 point gavage 1 time, Therapy lasted 9 weeks. In experimentation, there are indivedual animal injuries, finalEvery group of unification chosen 10 and added up. After experiment finishes, make mouse fasting 20 hours, point its body weight of another name, from eye socket veinGet blood, utilize related kit to measure every biochemical indicator. Each group data acquisition carries out statistical analysis with SPSS17.0, all dataAll withRepresent, group difference adopt one-way analysis of variance, with P < 0.05 for there being significant difference. Specific experiment resultStatistics is referring to table 2.
The every physiological and biochemical index of table 2 (n＝10)
With normal group comparison, ▲ P < 0.05, ▲ ▲ p < 0.01; With model group comparison, * P ﹤ 0.05, * * P ﹤ 0.01
From table 2:
(1) there is significant difference in the indices of normal group compared with model group, illustrates that the high confectionery thing of high fat has caused mouse blood sugarSerum lipid concentrations obviously raises, and ldl concn improves, and high-density lipoprotein concentration reduces, and body weight increases;
(2) compared with model group, positive controls Cr (Pic)3Fat-reducing effect unsatisfactory. Except body weight slightly lowers,All there were significant differences for all the other indexs;
(3) and compared with model group, the blood sugar of administration group reduces, and T-CHOL and triglycerides all obviously reduce, high density fatAlbumen raises, and body weight obviously reduces.
Cr(Pic)3It is current general hypoglycemic slimming medicine in the world. In this experiment, compare and positive controls compoundCr(Pic)3, the novel chromic compound [Cr (3-CH of synthesized3-SA)(Trientine)]Cl·H2O has good physiology hypoglycemicFat-reducing is active. This may be due to: 1) from chemical bond bond distance, the bond distance of boundary sum is than Cr (Pic) in this complex3To grow,Illustrate that this complexes stability is compared with Cr (Pic)3A little less than, in metabolic process, be easy to dissociate, chromium transport protein in the easy body of chromium ionTranshipment, makes bioavailability high; 2) the 3-methyl-salicylic acid structure in this complex molecule is similar to aspirin, hasThe effect of inhibition platelet aggregation etc.; 3) this complex is NaCl type, good water solubility, and bio-absorbable utilization rate is high.
Claims (9)
1. chromium (III) complex, is characterized in that, structural formula is:
2. the preparation method of a kind of chromium as claimed in claim 1 (III) complex, is characterized in that, comprises the steps:
1) by chromic salts and 3-methyl-salicylic acid organic solvent dissolution, drop into zinc granule, add hot reflux 1～3 hour, then splash intoTriethylene tetramine, continues to reflux at least 1～2 hours, stops reaction, cooling, filters;
2) filtrate obtaining is left standstill, under normal temperature, volatilization naturally, obtained aubergine crystal after three days.
3. the preparation method of chromium as claimed in claim 2 (III) complex, is characterized in that step 1) described chromic salts isChromium chloride, chromic nitrate or chromium sulfate.
4. the preparation method of chromium as claimed in claim 2 (III) complex, is characterized in that step 1) described chromic salts,The amount of substance ratio of 3-methyl-salicylic acid and zinc granule is 1: 1: 0.5～1.65.
5. the preparation method of chromium as claimed in claim 2 (III) complex, is characterized in that step 1) described chromic salts andThe amount of substance of triethylene tetramine is than being 1:50～100.
6. by the preparation method of chromium claimed in claim 2 (III) compound, it is characterized in that step 1) described zinc granule is20～50 object arsenic-free zinc granules.
7. the preparation method of chromium as claimed in claim 2 (III) complex, is characterized in that step 1) described organic solventFor methyl alcohol or ethanol.
8. chromium as claimed in claim 1 (III) complex is in the application of preparing in hypoglycemic medicine.
9. chromium as claimed in claim 1 (III) complex is in the application of preparing in slimming medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610146067.5A CN105601670B (en) | 2016-03-15 | 2016-03-15 | A kind of chromium (III) complex and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610146067.5A CN105601670B (en) | 2016-03-15 | 2016-03-15 | A kind of chromium (III) complex and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105601670A true CN105601670A (en) | 2016-05-25 |
| CN105601670B CN105601670B (en) | 2018-10-19 |
Family
ID=55982088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610146067.5A Expired - Fee Related CN105601670B (en) | 2016-03-15 | 2016-03-15 | A kind of chromium (III) complex and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105601670B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106220556A (en) * | 2016-07-21 | 2016-12-14 | 太原师范学院 | A kind of metformin pyridinedicarboxylic acid closes Cr (III) coordination compound and preparation method |
| CN108658849A (en) * | 2018-06-21 | 2018-10-16 | 太原师范学院 | A kind of Cr (III) complex and its preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070092461A1 (en) * | 2002-11-07 | 2007-04-26 | Bioderm Research | Novel Hydroxy Acid Complexes for Antiaging and Skin Renovation |
| CN102659844A (en) * | 2012-05-21 | 2012-09-12 | 山西大学 | Cr (III) chelate, and preparation method and application thereof |
| CN104513279A (en) * | 2015-01-15 | 2015-04-15 | 山西大学 | Cr (III) chelate compound as well as preparation method and application thereof |
-
2016
- 2016-03-15 CN CN201610146067.5A patent/CN105601670B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070092461A1 (en) * | 2002-11-07 | 2007-04-26 | Bioderm Research | Novel Hydroxy Acid Complexes for Antiaging and Skin Renovation |
| CN102659844A (en) * | 2012-05-21 | 2012-09-12 | 山西大学 | Cr (III) chelate, and preparation method and application thereof |
| CN104513279A (en) * | 2015-01-15 | 2015-04-15 | 山西大学 | Cr (III) chelate compound as well as preparation method and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| BIN LIU等，: "Synthesis, structure, stability and DNA cleavage activities of three Cr(III) complexes with salicylate and ammonium ligands", 《INORGANIC CHEMISTRY COMMUNICATIONS》 * |
| 刘斌等，: "[Cr(III)(4-ASA)(en)2]Cl配合物的光化学活性", 《化学学报》 * |
| 刘朝阳等，: "化合物[Cr(4-MSA)(TETA)]ClO4的制备表征及光谱性质", 《太原理工大学学报》 * |
| 南俊霞，: "5-氯水杨酸铬(III)配合物的制备、性质及降脂活性研究", 《山西大学2011届硕士学位论文》 * |
| 南俊霞等，: "两种5-氯水杨酸铬(III)配合物的合成及反应性研究", 《化学学报》 * |
| 南俊霞等，: "水杨酸衍生物铬(III)配合物的合成及性质研究", 《中国化学会第二十七届化学年会会议摘要》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106220556A (en) * | 2016-07-21 | 2016-12-14 | 太原师范学院 | A kind of metformin pyridinedicarboxylic acid closes Cr (III) coordination compound and preparation method |
| CN106220556B (en) * | 2016-07-21 | 2019-07-05 | 太原师范学院 | A kind of melbine pyridinedicarboxylic acid closes Cr (III) complex and preparation method |
| CN108658849A (en) * | 2018-06-21 | 2018-10-16 | 太原师范学院 | A kind of Cr (III) complex and its preparation method and application |
| CN108658849B (en) * | 2018-06-21 | 2021-08-13 | 太原师范学院 | Cr (III) complex and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105601670B (en) | 2018-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106879413A (en) | A kind of cultivation of selenium-rich blue or green money willow, extracts active ingredients and application | |
| CN109007800A (en) | A kind of specific full nutritional formulas and preparation method thereof for diabetic | |
| TWI598096B (en) | Preventive and / or therapeutic agents for side effects of anticancer agents | |
| CN105601670A (en) | Chromium (III) complex as well as preparation method and application thereof | |
| CN101032504A (en) | Application of liquiritin in medicines | |
| CN105061636A (en) | Preparation method of chitosan, citric acid and rare earth coordination compound | |
| JP2983171B2 (en) | New method for producing picolinic acid-chromium composite | |
| Vincent et al. | Introduction: A history of chromium studies (1955–2007) | |
| CN113616667A (en) | Nucleotide composition for adjuvant therapy of diabetes mellitus and preparation method and application thereof | |
| CN106220556B (en) | A kind of melbine pyridinedicarboxylic acid closes Cr (III) complex and preparation method | |
| CN104513279B (en) | Cr (III) chelate compound as well as preparation method and application thereof | |
| CN104497052B (en) | Trinuclear Cr(III) chelate as well as preparation method and application thereof | |
| CN108658849B (en) | Cr (III) complex and preparation method and application thereof | |
| CN104415023A (en) | Composition for preventing or/and treating insulin resistance and related diseases | |
| CN102659844A (en) | Cr (III) chelate, and preparation method and application thereof | |
| CN102550830A (en) | Method for applying and preparing gamma-aminobutyric acid complex compound | |
| CN107412261A (en) | With clear sugared oral liquid for repairing metabolic function and preparation method thereof | |
| CN109939135A (en) | A kind of raw ketone parenteral nutrient solution and preparation method thereof | |
| CN104042645B (en) | Compound amino acid injection | |
| CN101024653B (en) | 2-peroxo-vanadium-potassium salt complex, its preparing method and mono-crystal culture | |
| CN1090464C (en) | Health-care hypoglycermic edble salt and its preparing method | |
| CN104557990A (en) | Synthesis of zinc phenanthroline aminopolycarboxylate complex and application of complex in anti-tumor drugs | |
| JP3978582B2 (en) | Method for producing carotenoid | |
| CN103320387A (en) | Method for establishing mice transplantable breast cancer experimental pulmonary metastasis model | |
| CN113024450B (en) | Dithio-methyl cobalt (III) complex and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181019 Termination date: 20210315 |